ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Members will receive treatment until finally disease progression or maybe the participants are not able to tolerate the study drugs.Celastrol was determined for a Myb inhibitor that suppressed C/EBPβ exercise and repres